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Summan Piritrexim is a lipid-soluble drug which is as effectise an inhibitor of dihydrofolate reductase as
methotrexate. Phase I and II studies have indicated activity in some tumour types. Because of its lipophilicity
ue have conducted a phase II study in recurrent high-grade malignant glioma (grades III and IV). Twenty-
seven patients were treated with 25 mg p.o. three times daily for five consecutive days. repeated weekly. with
provision for dose escalation or reduction according to toxicity. Five patients received less than 4 weeks'
treatment because of disease progression or death. Twentv-two patients were evaluable for response. One
complete and one partial response was seen (duration 262+ and 241 + weeks) and 13 patients had static
disease for a median duration of 13 weeks (range 7-35). The major toxicity was myelosuppression. This
response rate of 90o of evaluable patients is much lower than that seen for some conventionally used drugs
and we conclude that piritrexim is unlikely to be of value in the management of high-grade gliomas.
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Piritrexim (2. 4-diamino-6- (2. 5-dimethoxybenzyl) -5-methyl-
pxridol[2.3-dnpvrimidine: BW 301U: PTX) is a lipid-soluble
inhibitor of dihydrofolate reductase (DHFR: Duch et al..
1982: Sedgick et al.. 1982: Sigel et al.. 1987). It enters cells
rapidly. is not polyglutamated intracellularly and is as potent
an inhibitor of DHFR in vitro as methotrexate (Duch et al..
1982). Activity against human tumour cells has been demon-
strated using the human tumour cloning assay in lung. ovar-.
colon and breast cancer (Neuenfeldt et al.. 1982: Marshall et
al.. 1985).
Intravenous administration causes peripheral phlebitis and.
as oral bioavailabilitv is around 75%o. oral dosing has been
recommended (Weiss et al.. 1989). A phase I study using
prolonged oral low-dose schedules has demonstrated an
acceptable regimen of 25 mg three times daily for 5 days out
of 7 for three consecutive weeks followed by 1 week without
PTX (Feun et al.. 1991). Myelosuppression was the main
dose-limiting toxicity. A paediatric phase I study has also
been reported (Adamson et al.. 1990).
Several phase II studies have now been reported. Anti-
tumour activitv has been seen in melanoma (Feun et al..
1991). head and neck cancer (Uen et al.. 1992). soft-tissue
sarcoma (Schiesel et al.. 1992) and metastatic urothelial
cancer (De Wit et al.. 1993a). Some activity was also seen in
non-small-cell lung cancer (Kris et al.. 1987) and in breast
cancer (de Vries et al.. 1993). However. little activity was
seen in a further study in head and neck cancer using a ven-
different schedule and in combination with methotrexate
(Vokes et al.. 1991). Because of the lipophilicity of PTX. we
have camred out a multicentre phase II study in recurrent
adult high-grade (grade 3 and 4) gliomas to assess its poten-
tial efficacy.
Correspondence: NM Bleehen
*Present address: Queensland Radium Institute. Royal Bn'sbane
Hospital. Herston. Australia Q4029
Received 10 March 1995. revised 4 Apn'l 1995: accepted '.Apn'l 1995
Patients and methods
Patients
Eligible patients were required to have histologically
confirmed high-grade (Kernohan grade III or IV) malignant
glioma which had relapsed after treatment by surgery.
radiotherapy or chemotherapy or a combination of these
modalities. Other entry criteria were (a) age 18-75 years: (b)
WHO performance status < 3: (c) neurological status < 3
(MRC scale): (d) estimated life expectancy of at least 8
weeks; (e) at least 6 weeks elapsed since radiotherapy or
previous chemotherapy: (f) no adjustment to steroid dose
within the previous week: (g) leucocyte count >4 x 109 I -I
and platelet count> 100 x 109 1-:1 (h) serum creatinine
level<l40mmol I': (i) serum bilirubin<25gmol 1'; (j)
aspartate transaminase (AST) or alanine transaminase (ALT)
<2 times normal: (k) alkaline phosphatase (ALP) < 2 times
normal. The protocol was approved by the local research
ethnics committee of the participating centres. Informed con-
sent was obtained from all patients before entry in the study.
Study design
Capsules of PTX were administered orally each day for five
consecutive days and repeated weekly after 2 days' rest. An
initial dose of 25 mg three times daily was continued through
the first four weekly cycles provided no toxicity (other than
grade 1 haemoglobin toxicity) was seen. In the absence of
any toxicity the dose was escalated to 25 mg four times daily.
This dose escalation schema. to titrate against toxicity. had
been defined in the phase I studies and used in phase II
studies (e.g. De Wit et al.. 1993a: de Vries et al..1993). If
grade 1 myelotoxicity was seen the dose remained un-
changed. If grade 2 myelotoxicity- was encountered within the
first 3 weeks (or grade 3 4 at any time) dosing wvas delaved
until recovery. at which point drug administration was
resumed at 25 mg t.d.s. for 4 days each week. A furtherPireim in recurent gionma
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reduction to 25 mg twice daily for 4 days was used in subse-
quent cycles if the toxicity was repeated. Antiemetics at all
doses of the chemotherapy were used to control nausea.
Patients continued on PTX until disease progression or unac-
ceptable toxicity.
Patients were seen weekly for assessment and for dose
adjustment during the first 12 weeks of the study and 4
weekly thereafter. Physical and neurological assessment and
of disease response was carried out 4 weekly. Computerised
tomographic (CT) and or magnetic resonance imaging (MRI)
examination was carried out to provide supplementary evid-
ence for objective response.
The Medical Research Council (MRC) neurological scale
was defined as: grade 0, no neurological deficit; grade 1.
some neurological deficit but function adequate for work;
grade 2, neurological deficit causing moderate functional
impairment; grade 3, neurological deficit causing major func-
tional impairment such as inability to use limb(s). gross
speech or visual disturbance; grade 4, no useful function with
inability to make conscious responses. An objective response
was defined as improvement of one or more neurological
symptoms to improve the neurological status by one grade
on the MRC scale. In addition, there should be no new
neurological deficits and the dose of steroids should be con-
stant. This objective response could be documented with or
without a tumour response as seen by imaging. This imaging
response was defined as a reduction of 50% or more in
tumour size, as the product of the two largest perpendicular
diameters of the lesion measured by CT or MRI. Stable
disease was defined as no change in neurological status
irrespective of change in tumour size but with constant
steroid dosage. Progressive disease was recorded when there
was a deterioration of neurological status and 'or increase in
steroid dose. To be evaluable for response, patients were
required to have completed at least four cycles of treatment.
The period of objective response was defined from the date
first observed to the date of the first observation of progres-
sive disease. Toxicity was recorded as defined by the WHO
toxicity scale (WHO, 1979).
Results
Twenty-eight patients were entered into the study. but one
was ineligible by reason of histology (grade 1) and was
withdrawn. The characteristics of the remaining 27 patients
are shown in Table I. Five patients were not evaluable for
response as they received less than 4 weeks' treatment. four
because of rapid clinical deterioration and one died in status
epilepticus after three weekly courses. These non-evaluable
patients remain included in the assessment of toxicity. Twelve
patients had previously received chemotherapy with either
the PCV regimen (procarbazine, CCNU and vincristine). or
single-agent nitrosoureas (CCNU/BCNU). Three patients
relapsing after PTX received subsequent chemotherapy, two
with PCV and one with CCNU alone.
Table I Patient characteristics
Number of eligible patients entered 27
Number evaluable 22
Gender (male female) 13 14
Median age (range) 45 (29-67)
WHO performance score 0 1 2 3 1 12 8 6
Pathological tumour grade 11 III IV 1 10 16
Prior treatment
Surgery
Biopsy only 5
Debulking
Radiotherapy 27
Chemotherapy 12
'Five patients are excluded from the response analysis because they
received less than 4 weeks' treatment but are included in the toxicits
assessment.
A total of 226 weekly courses was given in the 27 patients.
The median number of courses per patient was 7 (range
1 -27) and the median duration of treatment was 8 weeks
(range 1-37). The frequency of daill dosage per week was
increased from the initial three times per day to four times
per day in 17 patients and five times per day in eight
patients.
There were two responders in the 22 evaluable patients
(9%). or 7% of the 27 eligible patients entered into the study.
One of the 22 evaluable patients had a good clinical and
radiological complete response (CR) with a duration of res-
ponse of 262+ weeks. A second patient had a very good
partial response (PR) both radiologically and clinically,
receiving 17 courses of PTX before it was stopped because of
persistent mucositis. On subsequent relapse he responded
(PR) to CCNU and remains stable 241 + weeks after first
commencing PTX.
Of the remaining assessible patients. 13 (59% of evaluable.
48% of total eligible) were stable for a median time of 13
weeks (range 7-35). Disease progression following the start
of PTX was seen in the remaining seven patients. The median
survival time of all 27 eligible patients from the start of PTX
treatment was 26 weeks (range 4-241 +). and of the 22
assessible patients 30 weeks (range 4-241+).
Details of toxicity are given in Table II. The main toxicity
was haemopoietic with grade I or 2 leucopenia in 8 27
(30%). and neutropenia in 5 27 (19%). Thrombocytopenia
grade 1 or 2 occurred in 5 27 (1900). grade 3 in one patient
and grade 4 in two (7%). Mucositis. nausea and vomiting
and diarrhoea occurred in a few patients only. Alterations in
liver function tests were also noted. but were usually only
alterations in one biochemical parameter. Other minor tox-
icities (all grade 1 or 2) included somnolence (three cases)
and single cases of alopecia. dizziness. dryness of the eyes
and general malaise.
Discussion
The assessment of response to chemotherapy in high-grade
gliomas is not easy for a variety of reasons. which include
changes of clinical status dependent on steroid dosage. inter-
pretation of imaging results and persistence of clinical
disability as a result of the initial tumour and surgical
damage. (McDonald et al.. 1990). Complete responses are
rarely documented because normalisation of the radiological
appearance is unlikely as a result of brain destruction due to
tumour, surgery and the attendant changes following radio-
therapy. The two long-term responders in this study therefore
may be considered as worthwhile responses. More difficult to
interpret is the significance of the 59% of patients with static
disease. Patients who were entered into the study were on a
stable steroid dosage and with prior evidence of relapsing
tumour. Disease stability may therefore be interpreted as
evidence of some anti-tumour activity of the PTX. but this
conclusion needs to be accepted with caution.
The most active drugs reported include BCNU. CCNU.
MeCCNU. PCNU. procarbazine and dacarbazine. for which
Table II ToxicitV
WHO grade
Worst toxicity observed 0 1 2 3 4
Anaemia 17 7 3 0 0
Leucopenia 19 5 3 0 0
Neutropenia 22 3 2 0 0
Thrombocytopenia 19 1 4 1 2
Mucositis 23 4 0 0 0
Rash 22 5 0 0 0
Nausea vomiting 18 3 5 2 0
Diarrhoea 2 2 1 2 0
Hepatic' 17 3 6 1 0
'Elevation in one or more of the following parameters: alkaline
phosphatase. SGOT. SGPT. or y-glutamvltransaminase.
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response rates of 19-50°% have been reported (Lesser et al.,
1993). A newer drug. temozolomide. has been reported to
give a response in 5 10 (50%) patients (O'Reilly et al.. 1993).
In this context therefore it may be concluded that PTX has
only some limited activity in previously treated high-grade
gliomas.
Piritrexim was usually well tolerated. with myelotoxicity
being the main side-effect. This was variable and might
develop at any time during treatment but usually after dose
escalation. This has been previously reported and may
indicate variability of absorption (Weiss et al.. 1989).
Previous chemotherapy. in particular with a mntrosourea. may
also have contributed. Thus. of the 12 patients receiving
chemotherapy before PTX. toxicities ) grade 2 were seen for
total white cell count (WBC) in three (25%) and for platelets
in four (33%) patients. In the remaining 15 patients. assessed
for toxicity and previously not given chemotherapy. only one
grade 2 WBC toxicity was seen (13%). Other toxicities
included mucositis. skin rash. mild nausea and vomiting and
diarrhoea. All side-effects were rapidly reversible, but treat-
ment was stopped in three patients because of side-effects.
The significance of the mild hepatic changes was uncertain.
Pulmonary toxicity induced by PTX, as described by De Wit
et al. (1993b). was not seen in this study. There were no
drug-related deaths although one patient died in status
epilepticus 3 weeks after commencing treatment.
The studies previously reported with PTX in other diseases
did not demonstrate better activity than might have been
expected from a more conventional antifolate such as
methotrexate. Pubhshed phase II studies that have reported
responses include those with little activity. such as 2 26
(11%) in soft-tissue sarcoma (Schiesel et al.. 1992), 5 28
(17%) in head and neck cancer (Vokes et al.. 1991). 10 66
(15%) in non-small-cell lung cancer (Kris et al.. 1987) and
1 24 (4%) in breast cancer (De Vnres et al.. 1993). Other
studies have reported better response rates in squamous head
and neck cancer 9 33 (27%) including three CRs (Uen et al..
1992) and 7 31 (23%) in malignant melanoma with two CRs
(Feun et al.. 1991). Only in the report on a phase II trial in
metastatic urothelial cancer was a high response rate of 11 29
(38%) with one CR seen. but as the authors indicated this is
similar to that seen with methotrexate (De Wit et al.. 1993a).
In this present study the expectation that the lipophilicity of
PTX might provide an additional drug with a worthwhile
response rate in brain tumours. which might then take its
place in a combination regimen with a nitrosourea, has not
been justified. In spite of the two good responses. the results
of this study are inferior to those reported with other drugs
currently available.
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